ACTO CEO Parth Khanna on why sales reps still matter — and how human intelligence plus empathetic agents is the winning formula for field teams.

Pharmaceutical Executive spoke with K2 Therapeutics’ CEO Dr. Ying Huang about the growing shift towards globally sourced innovation and the increased focus on foreign partnerships. The push has become ...

Beyond tau and TREM2: checkpoint inhibition, inflammasome drugs, brain delivery technologies, and biomarker-led diagnostics reshape Alzheimer's pipeline.

The FDA has approved daraxonrasib (brand name Rasonque) for adults with metastatic pancreatic adenocarcinoma who have ...

A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike major ...

President Donald Trump’s administration is preparing to announce a new round of drug-pricing agreements with midsize biotech ...

Eli Lilly and Company announced results from a real-world study of adults over 55 with obesity or overweight showing that ...

Biohaven grants SK Biopharmaceuticals an exclusive worldwide license to its Kv7 ion channel platform, while Haisco licenses a preclinical type 2 inflammatory disease asset to newly formed Sentivera.

FDA approves Imaavy as the first treatment for warm autoimmune hemolytic anemia, McKesson agrees to acquire Precision ...

Most Phase 2 trials are sized on a guess seen as mathematics. You are in the trial design meeting, your biostatistician pulls up a standard power calculation, someone picks an effect size that feels ...

ACTO's co-founder on why AI trust equals compliant plus capable — and why role-specific context is what allows agents to achieve both. Over recent years, the pharmaceutical industry has generally ...

Evolving global expectations for CGT validation, comparability, and supply continuity elevate the need for operational and ...